Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
4D Molecular Therapeutics (NASDAQ:FDMT) is under investigation by The Schall Law Firm for potential securities law violations. The investigation centers on whether the company made false or misleading statements to investors. Despite the company presenting positive interim results from its Phase 2 PRISM study on Intravitreal 4D-150 on July 17, 2024, the stock experienced a significant decline of over 35.8% in afternoon trading on the same day. The law firm is encouraging affected shareholders to participate in the investigation.
4D Molecular Therapeutics (NASDAQ:FDMT) è sotto indagine da parte dello Schall Law Firm per potenziali violazioni delle leggi sui titoli. L'indagine si concentra sull'eventualità che la società abbia rilasciato dichiarazioni false o fuorvianti agli investitori. Nonostante la società abbia presentato risultati positivi provvisori del suo studio di Fase 2 PRISM su Intravitreal 4D-150 il 17 luglio 2024, il titolo ha subito un notevole calo di oltre 35,8% nel trading pomeridiano dello stesso giorno. Lo studio legale incoraggia gli azionisti colpiti a partecipare all'indagine.
4D Molecular Therapeutics (NASDAQ:FDMT) está siendo investigada por Schall Law Firm por posibles violaciones de leyes de valores. La investigación se centra en si la empresa hizo declaraciones falsas o engañosas a los inversores. A pesar de que la empresa presentó resultados interinos positivos de su estudio de Fase 2 PRISM sobre Intravitreal 4D-150 el 17 de julio de 2024, la acción experimentó una caída significativa de más del 35.8% en el comercio de la tarde del mismo día. El bufete de abogados está alentando a los accionistas afectados a participar en la investigación.
4D Molecular Therapeutics (NASDAQ:FDMT)는 증권법 위반 가능성으로 인해 Schall Law Firm의 조사를 받고 있습니다. 이번 조사는 회사가 투자자들에게 허위 또는 오해의 소지가 있는 발언을 했는지에 대한 것입니다. 2024년 7월 17일, 회사가 Intravitreal 4D-150에 대한 2상 PRISM 연구의 긍정적인 중간 결과를 발표했음에도 불구하고, 주가는 같은 날 오후 거래에서 35.8% 이상 급락했습니다. 법무법인은 영향 받은 주주들이 조사에 참여할 것을 권장하고 있습니다.
4D Molecular Therapeutics (NASDAQ:FDMT) fait l'objet d'une enquête par le Schall Law Firm pour d'éventuelles violations des lois sur les valeurs mobilières. L'enquête porte sur la question de savoir si l'entreprise a fait des déclarations fausses ou trompeuses aux investisseurs. Bien que l'entreprise ait présenté des résultats intermédiaires positifs de son étude de Phase 2 PRISM sur Intravitreal 4D-150 le 17 juillet 2024, l'action a connu une baisse significative de plus de 35,8% lors des échanges de l'après-midi du même jour. Le cabinet d'avocats encourage les actionnaires concernés à participer à l'enquête.
4D Molecular Therapeutics (NASDAQ:FDMT) wird von der Schall Law Firm wegen möglicher Verstöße gegen das Wertpapierrecht untersucht. Die Untersuchung konzentriert sich darauf, ob das Unternehmen falsche oder irreführende Aussagen gegenüber Investoren gemacht hat. Trotz der Präsentation positiver vorläufiger Ergebnisse der Phase-2-PRISM-Studie zu Intravitreal 4D-150 am 17. Juli 2024 erlebte die Aktie am gleichen Tag im nachmittäglichen Handel einen signifikanten Rückgang von über 35,8%. Die Kanzlei ermutigt betroffene Aktionäre, an der Untersuchung teilzunehmen.
- None.
- Stock price dropped 35.8% following Phase 2 PRISM study results announcement
- Company faces securities law violation investigation
- Potential misleading statements to investors regarding clinical trial results
Insights
This shareholder investigation represents a significant legal risk for 4D Molecular Therapeutics. The 35.8% stock drop following their Phase 2 PRISM study results announcement has triggered scrutiny over potential securities law violations. The investigation's focus on misleading statements about clinical trial results could lead to substantial financial penalties and settlement costs if violations are found.
The timing and nature of the stock drop suggest a material disconnect between the company's characterization of the results as positive and the market's interpretation. Securities class actions typically examine whether companies adequately disclosed risks and accurately represented clinical trial data. If the investigation reveals discrepancies, it could result in significant legal expenses, reputational damage and potential settlement payouts that could impact the company's
LOS ANGELES, CA / ACCESSWIRE / October 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. 4D Molecular Therapeutics released the interim results of its Phase 2 PRISM study on Intravitreal 4D-150 on July 17, 2024. Despite the Company billing the results as positive, the stock fell by more than
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com
SOURCE: The Schall Law Firm
View the original press release on accesswire.com
FAQ
Why did 4D Molecular Therapeutics (FDMT) stock drop 35.8% on July 17, 2024?
What is the investigation against 4D Molecular Therapeutics (FDMT) about?
When did The Schall Law Firm announce its investigation of FDMT?
